ArticleJournal of arrhythmia2025
Undiagnostic Heart Failure With Preserved Ejection Fraction in Atrial Fibrillation Patients Undergoing Catheter Ablation.
Article in Journal of arrhythmia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Undiagnostic Heart Failure With Preserved Ejection Fraction in Atrial Fibrillation Patients Undergoing Catheter Ablation.Journal of arrhythmia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) often coexist, but the prevalence of HFpEF among AF patients undergoing catheter ablation (CA) remains unclear. Methods: We studied 127 AF patients with preserved ejection fraction (≥ 50%) undergoing initial CA. The Heart Failure Association Pre-test assessment, Echocardiography and natriuretic peptides, Functional testing, and Final etiology (HFA-PEFF) score was assessed 2 weeks before and 1 year after CA. Patients were grouped as low (0-1), intermediate (2-4), or high (5-6). The primary endpoint was AF freedom at 1 and 2 years; secondary endpoints were changes in HFA-PEFF score; tertiary endpoint was predictors of score improvement. Results: Of 127 patients, 30 (23.6%) had HFpEF (score ≥ 5), 76 (59.8%) suspected (2-4), and 21 (16.5%) unlikely (≤ 1). Median follow-up 24.4[ 12.5-29.5] months. AF freedom at 1 year was high (86.4%, 91.7%, 89.7%; Conclusions: HFpEF or suspected HFpEF was common in AF CA candidates but not linked to recurrence. CA remarkably improved HFpEF features, suggesting reversibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.